Recent News

• 03.25.2026 - bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice
• 03.17.2026 - New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures
• 03.13.2026 - bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® Lung
• 03.10.2026 - bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic
• 03.03.2026 - bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma Patients
• 02.25.2026 - bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

Recent Filings

• 03.17.2026 - EX-99.1 EX-99.1
• 03.17.2026 - 8-K Current report
• 03.16.2026 - DEF 14A Other definitive proxy statements
• 03.16.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.16.2026 - ARS Annual Report to Security Holders
• 03.13.2026 - EX-99.1 EX-99.1
• 03.13.2026 - 8-K Current report
• 03.10.2026 - 8-K Current report
• 03.10.2026 - EX-99.1 EX-99.1
• 03.06.2026 - 8-K Current report